Progress in emerging therapies for advanced prostate cancer.
about
Gonadotropin-releasing hormone agonists sensitize, and resensitize, prostate cancer cells to docetaxel in a p53-dependent mannerTreatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world dataMETastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer.Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utilityPigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.Androgen Deprivation Therapy and the Re-emergence of Parenteral Estrogen in Prostate Cancer.Enzalutamide for patients with metastatic castration-resistant prostate cancerClinical management and burden of prostate cancer: a Markov Monte Carlo model.Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistanceA prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer.Prostate cancer: the need for biomarkers and new therapeutic targets.Autophagy in prostate cancer and androgen suppression therapy.Enzalutamide (Xtandi) for patients with metastatic, resistant prostate cancer.Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer.Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence.Down-modulation of Bcl-2 sensitizes PTEN-mutated prostate cancer cells to starvation and taxanes.Synergistic antitumor cytotoxic actions of ascorbate and menadione on human prostate (DU145) cancer cells in vitro: nucleus and other injuries preceding cell death by autoschizis.Targeted delivery of Epirubicin to cancer cells by PEGylated A10 aptamer.Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 StudiesEfficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.Cancer-related inflammation: an emerging prognostic domain in metastatic castration-resistant prostate carcinoma.
P2860
Q28537723-8EBDB962-1F54-4BEE-B881-7C3BA872F9D0Q31034242-F2B6AB8B-E0D1-4325-B9E6-52CD820989DFQ31108842-971AC7E3-520A-4CDE-A487-A28EAD4C88B6Q33656820-E00D04D1-65BB-4788-9B02-76A3A9146695Q33720164-111113F8-640F-4E6D-8205-24E4676D3C23Q33736308-1D003A81-6DD1-4626-B906-1D66390EA912Q34475171-56D0810B-2C13-4529-8C1A-E3DAD4193097Q34634410-17F77474-38F1-4376-98AE-EFED054753AEQ36398998-411027BC-0B5F-4AC6-B39F-C0BA743E90D0Q36470627-5063E294-CDD5-4E5B-A281-6E83E055B4A7Q36776738-2D9C892C-45D9-4A2F-8438-9006CF68EB21Q37476043-F8FF024D-3464-4B6B-ACA0-070088706121Q38112596-0ADEFCD1-EA19-429F-86B2-70BF5B92D2D7Q38181433-47A4E724-75D9-4157-AB41-66B4E0DDA2CCQ38643148-CCEA4F9F-2BD1-48F1-BE66-5FC6BF7F32B9Q38797560-F68482BE-D1BE-4325-BCDD-F48DD38E6633Q38856091-AB50125E-C17B-4CFF-8E40-C733396DBED6Q38967167-6B2F03CF-F5C6-4F1F-950A-99379C137FA0Q39031038-30C2DEC0-519B-453A-818D-B04A3C29F7BDQ39132440-FB496B28-4C81-4F50-A16E-346E83F102F3Q39612278-C701FD74-1DB1-4ECE-B6C1-431B61BD9E51Q41382610-7ADD3E74-AA81-4765-B150-5A4D74A009B9Q41841139-D2F37080-93A1-404A-B06E-BDFDBC8187A6Q42467386-F34A76D2-A33F-46EA-B5C8-10D5922A0B54Q53036820-EB14785B-71A6-46DE-957C-8F02C73419BB
P2860
Progress in emerging therapies for advanced prostate cancer.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Progress in emerging therapies for advanced prostate cancer.
@ast
Progress in emerging therapies for advanced prostate cancer.
@en
Progress in emerging therapies for advanced prostate cancer.
@nl
type
label
Progress in emerging therapies for advanced prostate cancer.
@ast
Progress in emerging therapies for advanced prostate cancer.
@en
Progress in emerging therapies for advanced prostate cancer.
@nl
prefLabel
Progress in emerging therapies for advanced prostate cancer.
@ast
Progress in emerging therapies for advanced prostate cancer.
@en
Progress in emerging therapies for advanced prostate cancer.
@nl
P1476
Progress in emerging therapies for advanced prostate cancer.
@en
P2093
Stéphane Oudard
P304
P356
10.1016/J.CTRV.2012.09.005
P577
2012-10-26T00:00:00Z